Details of the Drug

General Information of Drug (ID: DMPDW6T)

Drug Name
Epirubicin
Synonyms
Ellence; Epiadriamycin; Epidoxorubicin; Epirubicina; Epirubicine; Epirubicinum; Pidorubicin; Pidorubicina; Pidorubicine; Pidorubicinum; Ridorubicin; Epirubicina [Spanish]; Epirubicine [French]; Epirubicinum [Latin]; Pharmorubicin Pfs; IMI 28; WP 697; Ebewe (TN); Ellence (TN); Epi-DX; Epirubicin (INN); Epirubicin (TN); Epirubicin [INN:BAN]; Epirubicina [INN-Spanish]; Epirubicine [INN-French]; Epirubicinum [INN-Latin]; Farmorubicin (TN); Pharmorubicin (TN); Pidorubicina [INN-Spanish]; Pidorubicine [INN-French]; Pidorubicinum [INN-Latin]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside; (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione; 4'-Epi-DXR; 4'-Epiadriamycin; 4'-epi-DX; 4'-epi-Doxorubicin; 4'-epidoxorubicin; 4-Epidoxorubicin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 543.5
Topological Polar Surface Area (xlogp) 1.3
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
Absorption
The absorption of drug is 100% [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [4]
Elimination
9.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 minutes (alpha), 2.5 hours (beta), and 33 hours (gamma) [4]
Metabolism
The drug is metabolized via the liver [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.7524 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [4]
Vd
The volume of distribution (Vd) of drug is 21 +/- 2 L/kg [6]
Chemical Identifiers
Formula
C27H29NO11
IUPAC Name
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
InChIKey
AOJJSUZBOXZQNB-VTZDEGQISA-N
Cross-matching ID
PubChem CID
41867
ChEBI ID
CHEBI:47898
CAS Number
56420-45-2
DrugBank ID
DB00445
TTD ID
D0C9XJ
VARIDT ID
DR00170
INTEDE ID
DR0591

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Epirubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [60]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [60]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Epirubicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [61]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Epirubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [61]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [62]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [61]
Methyltestosterone DMWLFGO Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Methyltestosterone. Solid tumour/cancer [2A00-2F9Z] [60]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Epirubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [60]
Tretinoin DM49DUI Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tretinoin. Acne vulgaris [ED80] [60]
Isotretinoin DM4QTBN Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Isotretinoin. Acne vulgaris [ED80] [60]
Nicotinamide DMUPE07 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Nicotinamide. Acquired cutaneous blood vessel malformation [EF20] [60]
Pioglitazone DMKJ485 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Pioglitazone. Acute diabete complication [5A2Y] [60]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Epirubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [63]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tagraxofusp. Acute myeloid leukaemia [2A60] [60]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Midostaurin. Acute myeloid leukaemia [2A60] [61]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Idarubicin. Acute myeloid leukaemia [2A60] [61]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Daunorubicin. Acute myeloid leukaemia [2A60] [61]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Arn-509. Acute myeloid leukaemia [2A60] [62]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [64]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Oliceridine. Acute pain [MG31] [61]
Oxandrolone DMU9MYJ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Oxandrolone. Alcoholic liver disease [DB94] [60]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Galantamine. Alzheimer disease [8A20] [61]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Rivastigmine. Alzheimer disease [8A20] [61]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Donepezil. Alzheimer disease [8A20] [61]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Epirubicin and Metronidazole. Amoebiasis [1A36] [60]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Epirubicin and Ivabradine. Angina pectoris [BA40] [62]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Epirubicin and Bepridil. Angina pectoris [BA40] [61]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Epirubicin and Dronedarone. Angina pectoris [BA40] [61]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Epirubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [65]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [61]
Oxymetholone DMFXUT8 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Oxymetholone. Aplastic anaemia [3A70] [60]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Cilostazol. Arterial occlusive disease [BD40] [61]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Voriconazole. Aspergillosis [1F20] [61]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Posaconazole. Aspergillosis [1F20] [61]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Levalbuterol. Asthma [CA23] [66]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Terbutaline. Asthma [CA23] [67]
Zafirlukast DMHNQOG Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Zafirlukast. Asthma [CA23] [60]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pirbuterol. Asthma [CA23] [67]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Salbutamol. Asthma [CA23] [66]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Epirubicin and Roflumilast. Asthma [CA23] [62]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Formoterol. Asthma [CA23] [67]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [62]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Desipramine. Attention deficit hyperactivity disorder [6A05] [61]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ofloxacin. Bacterial infection [1A00-1C4Z] [68]
Clavulanate DM2FGRT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Clavulanate. Bacterial infection [1A00-1C4Z] [60]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [61]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Clarithromycin. Bacterial infection [1A00-1C4Z] [61]
Trovafloxacin DM6AN32 Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [69]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Epirubicin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [61]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Epirubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [68]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [68]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Norfloxacin. Bacterial infection [1A00-1C4Z] [68]
ABT-492 DMJFD2I Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [69]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Levofloxacin. Bacterial infection [1A00-1C4Z] [68]
Minocycline DMVN5OH Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Minocycline. Bacterial infection [1A00-1C4Z] [60]
Lomefloxacin DMVRH9C Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [69]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Retigabine. Behcet disease [4A62] [61]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Epirubicin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [70]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Loperamide. Bowel habit change [ME05] [71]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Eribulin. Breast cancer [2C60-2C6Y] [61]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lapatinib. Breast cancer [2C60-2C6Y] [61]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and LY2835219. Breast cancer [2C60-2C6Y] [60]
Tucatinib DMBESUA Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [72]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tamoxifen. Breast cancer [2C60-2C6Y] [61]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Epirubicin and Toremifene. Breast cancer [2C60-2C6Y] [61]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Epirubicin and Sotalol. Cardiac arrhythmia [BC9Z] [61]
Atorvastatin DMF28YC Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [60]
Chenodiol DMQ8JIK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Chenodiol. Cholelithiasis [DC11] [60]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [73]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [67]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [66]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [67]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [67]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [67]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Isoproterenol. Conduction disorder [BC63] [66]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Halothane. Corneal disease [9A76-9A78] [61]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Propofol. Corneal disease [9A76-9A78] [74]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Sevoflurane. Corneal disease [9A76-9A78] [61]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Probucol. Coronary atherosclerosis [BA80] [61]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Clofazimine. Crohn disease [DD70] [75]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Epirubicin and Pasireotide. Cushing syndrome [5A70] [61]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Osilodrostat. Cushing syndrome [5A70] [62]
Ivacaftor DMZC1HS Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ivacaftor. Cystic fibrosis [CA25] [60]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Sertraline. Depression [6A70-6A7Z] [61]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Trimipramine. Depression [6A70-6A7Z] [61]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Imipramine. Depression [6A70-6A7Z] [61]
Fluoxetine DM3PD2C Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Fluoxetine. Depression [6A70-6A7Z] [61]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Nortriptyline. Depression [6A70-6A7Z] [61]
Nefazodone DM4ZS8M Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Nefazodone. Depression [6A70-6A7Z] [60]
Duloxetine DM9BI7M Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Duloxetine. Depression [6A70-6A7Z] [60]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Epirubicin and Escitalopram. Depression [6A70-6A7Z] [61]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Clomipramine. Depression [6A70-6A7Z] [61]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Trazodone. Depression [6A70-6A7Z] [76]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Amoxapine. Depression [6A70-6A7Z] [61]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Doxepin. Depression [6A70-6A7Z] [61]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Maprotiline. Depression [6A70-6A7Z] [61]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [60]
PMID28454500-Compound-96 DM2A75P Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and PMID28454500-Compound-96. Discovery agent [N.A.] [60]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [61]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Deutetrabenazine. Dystonic disorder [8A02] [77]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ingrezza. Dystonic disorder [8A02] [78]
Felbamate DM1V5ZS Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Felbamate. Epilepsy/seizure [8A61-8A6Z] [60]
Fosphenytoin DMOX3LB Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [60]
Carbamazepine DMZOLBI Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [60]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Cannabidiol. Epileptic encephalopathy [8A62] [60]
Dantrolene DM1D8XY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Dantrolene. Fever [MG26] [60]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Solifenacin. Functional bladder disorder [GC50] [61]
Itraconazole DMCR1MV Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Itraconazole. Fungal infection [1F29-1F2F] [60]
Caspofungin DMGQIPT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Caspofungin. Fungal infection [1F29-1F2F] [60]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pentamidine. Fungal infection [1F29-1F2F] [61]
Terbinafine DMI6HUW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Terbinafine. Fungal infection [1F29-1F2F] [60]
Ketoconazole DMPZI3Q Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ketoconazole. Fungal infection [1F29-1F2F] [60]
Atovaquone DMY4UMW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Atovaquone. Fungal infection [1F29-1F2F] [60]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Epirubicin and Cisapride. Gastro-oesophageal reflux disease [DA22] [61]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [61]
Lamivudine DMI347A Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lamivudine. Hepatitis virus infection [1E50-1E51] [60]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [60]
Isoniazid DM5JVS3 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [60]
Rifampin DMA8J1G Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [60]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [60]
Zidovudine DM4KI7O Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Zidovudine. Human immunodeficiency virus disease [1C60-1C62] [60]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [79]
Stavudine DM6DEK9 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Stavudine. Human immunodeficiency virus disease [1C60-1C62] [60]
Tipranavir DM8HJX6 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [60]
Emtricitabine DMBMUWZ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Emtricitabine. Human immunodeficiency virus disease [1C60-1C62] [60]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Epirubicin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [80]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Epirubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [81]
Zalcitabine DMH7MUV Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [60]
Didanosine DMI2QPE Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Didanosine. Human immunodeficiency virus disease [1C60-1C62] [60]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [61]
Abacavir DMMN36E Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Abacavir. Human immunodeficiency virus disease [1C60-1C62] [60]
Darunavir DMN3GCH Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Darunavir. Human immunodeficiency virus disease [1C60-1C62] [60]
Maraviroc DMTL94F Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [60]
Ritonavir DMU764S Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ritonavir. Human immunodeficiency virus disease [1C60-1C62] [60]
Simvastatin DM30SGU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Simvastatin. Hyper-lipoproteinaemia [5C80] [60]
Fluvastatin DM4MDJY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fluvastatin. Hyper-lipoproteinaemia [5C80] [60]
Fenofibrate DMFKXDY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fenofibrate. Hyper-lipoproteinaemia [5C80] [60]
Rosuvastatin DMMIQ7G Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [60]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Epirubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [82]
BMS-201038 DMQTAGO Moderate Decreased clearance of Epirubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [83]
Moexipril DM26E4B Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Moexipril. Hypertension [BA00-BA04] [60]
Captopril DM458UM Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Captopril. Hypertension [BA00-BA04] [60]
Trandolapril DM4L6EU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Trandolapril. Hypertension [BA00-BA04] [60]
Methyldopa DM5I621 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Methyldopa. Hypertension [BA00-BA04] [60]
Fosinopril DM9NJ52 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fosinopril. Hypertension [BA00-BA04] [60]
Labetalol DMK8U72 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Labetalol. Hypertension [BA00-BA04] [60]
Enalapril DMNFUZR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Enalapril. Hypertension [BA00-BA04] [60]
Perindopril DMOPZDT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Perindopril. Hypertension [BA00-BA04] [60]
Quinapril DMR8H31 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Quinapril. Hypertension [BA00-BA04] [60]
Lisinopril DMUOK4C Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lisinopril. Hypertension [BA00-BA04] [60]
Tolvaptan DMIWFRL Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [60]
Vitamin B3 DMQVRZH Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Vitamin B3. Inborn lipid metabolism error [5C52] [60]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [60]
Febuxostat DMDEXQ0 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Febuxostat. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [60]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [62]
Testosterone DM7HUNW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Testosterone. Low bone mass disorder [FB83] [60]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Epirubicin and Denosumab. Low bone mass disorder [FB83] [84]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Epirubicin and Crizotinib. Lung cancer [2C25] [85]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Epirubicin and Porfimer Sodium. Lung cancer [2C25] [86]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Epirubicin and Ceritinib. Lung cancer [2C25] [61]
Erlotinib DMCMBHA Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Erlotinib. Lung cancer [2C25] [60]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lurbinectedin. Lung cancer [2C25] [60]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Alectinib. Lung cancer [2C25] [60]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Epirubicin and Osimertinib. Lung cancer [2C25] [87]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and BIBW 2992. Lung cancer [2C25] [60]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Pralsetinib. Lung cancer [2C25] [60]
Capmatinib DMYCXKL Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [88]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Epirubicin and Selpercatinib. Lung cancer [2C25] [62]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Epirubicin and Lumefantrine. Malaria [1F40-1F45] [60]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Epirubicin and Halofantrine. Malaria [1F40-1F45] [89]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Epirubicin and Chloroquine. Malaria [1F40-1F45] [90]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Epirubicin and Hydroxychloroquine. Malaria [1F40-1F45] [90]
Quinine DMSWYF5 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Quinine. Malaria [1F40-1F45] [61]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Primaquine. Malaria [1F40-1F45] [61]
Sulphadoxine DMZI2UF Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Sulphadoxine. Malaria [1F40-1F45] [60]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [62]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [60]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and IPI-145. Mature B-cell leukaemia [2A82] [60]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Epirubicin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [91]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Clofarabine. Mature B-cell lymphoma [2A85] [92]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Blinatumomab. Mature B-cell lymphoma [2A85] [60]
Vincristine DMINOX3 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Vincristine. Mature B-cell lymphoma [2A85] [60]
Cytarabine DMZD5QR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Cytarabine. Mature B-cell lymphoma [2A85] [60]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Arry-162. Melanoma [2C30] [60]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Epirubicin and Vemurafenib. Melanoma [2C30] [61]
Ipilimumab DMJTIYK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ipilimumab. Melanoma [2C30] [60]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and LGX818. Melanoma [2C30] [93]
Danazol DML8KTN Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Danazol. Menstrual cycle bleeding disorder [GA20] [60]
Riluzole DMECBWN Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Riluzole. Motor neuron disease [8B60] [60]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Epirubicin and Panobinostat. Multiple myeloma [2A83] [94]
Lenalidomide DM6Q7U4 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Lenalidomide. Multiple myeloma [2A83] [60]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Epirubicin and Thalidomide. Multiple myeloma [2A83] [95]
Elotuzumab DMEYHG9 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Elotuzumab. Multiple myeloma [2A83] [60]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tecfidera. Multiple sclerosis [8A40] [60]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Epirubicin and Siponimod. Multiple sclerosis [8A40] [60]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Epirubicin and Fingolimod. Multiple sclerosis [8A40] [96]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Epirubicin and Ozanimod. Multiple sclerosis [8A40] [62]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Romidepsin. Mycosis fungoides [2B01] [61]
Fedratinib DM4ZBK6 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fedratinib. Myeloproliferative neoplasm [2A20] [60]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Epirubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [61]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [97]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Epirubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [98]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Epirubicin and Droperidol. Nausea/vomiting [MD90] [61]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Promethazine. Nausea/vomiting [MD90] [61]
Rolapitant DM8XP26 Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [99]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Epirubicin and Dolasetron. Nausea/vomiting [MD90] [61]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Ondansetron. Nausea/vomiting [MD90] [61]
Bupropion DM5PCS7 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Bupropion. Nicotine use disorder [6C4A] [60]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Entrectinib. Non-small cell lung cancer [2C25] [60]
Orlistat DMRJSP8 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Orlistat. Obesity [5B80-5B81] [60]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Epirubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [62]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lofexidine. Opioid use disorder [6C43] [61]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Rucaparib. Ovarian cancer [2C73] [61]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Dextropropoxyphene. Pain [MG30-MG3Z] [100]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Buprenorphine. Pain [MG30-MG3Z] [61]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Triclabendazole. Parasitic worm infestation [1F90] [61]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pimavanserin. Parkinsonism [8A00] [101]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Apomorphine. Parkinsonism [8A00] [61]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Famotidine. Peptic ulcer [DA61] [60]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Epirubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [102]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Epirubicin and Lefamulin. Pneumonia [CA40] [103]
Lonafarnib DMGM2Z6 Moderate Decreased clearance of Epirubicin due to the transporter inhibition by Lonafarnib. Premature ageing appearance [LD2B] [104]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Ritodrine. Preterm labour/delivery [JB00] [67]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Degarelix. Prostate cancer [2C82] [62]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Epirubicin and ABIRATERONE. Prostate cancer [2C82] [62]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Nilutamide. Prostate cancer [2C82] [62]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Enzalutamide. Prostate cancer [2C82] [62]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Flutamide. Prostate cancer [2C82] [62]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Relugolix. Prostate cancer [2C82] [62]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Bicalutamide. Prostate cancer [2C82] [62]
Acitretin DM8BKU9 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Acitretin. Psoriasis [EA90] [60]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Levomepromazine. Psychotic disorder [6A20-6A25] [61]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Fluphenazine. Psychotic disorder [6A20-6A25] [61]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Triflupromazine. Psychotic disorder [6A20-6A25] [61]
Ambrisentan DMD1QXW Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Ambrisentan. Pulmonary hypertension [BB01] [60]
Bosentan DMIOGBU Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Bosentan. Pulmonary hypertension [BB01] [60]
Axitinib DMGVH6N Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Axitinib. Renal cell carcinoma [2C90] [60]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Epirubicin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [105]
Tocilizumab DM7J6OR Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Tocilizumab. Rheumatoid arthritis [FA20] [60]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Epirubicin and Canakinumab. Rheumatoid arthritis [FA20] [106]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Epirubicin and Rilonacept. Rheumatoid arthritis [FA20] [106]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Epirubicin and Golimumab. Rheumatoid arthritis [FA20] [107]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Sarilumab. Rheumatoid arthritis [FA20] [60]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Epirubicin and Leflunomide. Rheumatoid arthritis [FA20] [82]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Quetiapine. Schizophrenia [6A20] [61]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Epirubicin and Mesoridazine. Schizophrenia [6A20] [61]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Epirubicin and Thioridazine. Schizophrenia [6A20] [61]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Aripiprazole. Schizophrenia [6A20] [60]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Epirubicin and Iloperidone. Schizophrenia [6A20] [61]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Paliperidone. Schizophrenia [6A20] [61]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Epirubicin and Haloperidol. Schizophrenia [6A20] [61]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Perphenazine. Schizophrenia [6A20] [61]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Chlorpromazine. Schizophrenia [6A20] [61]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Risperidone. Schizophrenia [6A20] [61]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Epirubicin and Amisulpride. Schizophrenia [6A20] [108]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Asenapine. Schizophrenia [6A20] [61]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Epirubicin and Pimozide. Schizophrenia [6A20] [62]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Epirubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [109]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Vardenafil. Sexual dysfunction [HA00-HA01] [61]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Pitolisant. Somnolence [MG42] [61]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [61]
Disulfiram DMCL2OK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Disulfiram. Substance abuse [6C40] [60]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Naltrexone. Substance abuse [6C40] [60]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Epirubicin and Adenosine. Supraventricular tachyarrhythmia [BC81] [61]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Fostamatinib. Thrombocytopenia [3B64] [60]
Eltrombopag DMOGFIX Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Eltrombopag. Thrombocytopenia [3B64] [60]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Lenvatinib. Thyroid cancer [2D10] [61]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Epirubicin and Cabozantinib. Thyroid cancer [2D10] [62]
Propylthiouracil DM6D7N8 Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Propylthiouracil. Thyrotoxicosis [5A02] [60]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Epirubicin and Papaverine. Tonus and reflex abnormality [MB47] [110]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tizanidine. Tonus and reflex abnormality [MB47] [61]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Epirubicin and Azathioprine. Transplant rejection [NE84] [60]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Tacrolimus. Transplant rejection [NE84] [61]
Cinoxacin DM4EWNS Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [69]
Nitrofurantoin DM7PQIK Moderate Increased risk of hepatotoxicity by the combination of Epirubicin and Nitrofurantoin. Urinary tract infection [GC08] [60]
Nalidixic acid DMRM0JV Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [69]
Enoxacin DMYTE6L Minor Decreased absorption of Epirubicin due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [69]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Astemizole. Vasomotor/allergic rhinitis [CA08] [61]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [100]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Epirubicin and Procainamide. Ventricular tachyarrhythmia [BC71] [61]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Propafenone. Ventricular tachyarrhythmia [BC71] [61]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Epirubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [61]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Epirubicin and Amiodarone. Ventricular tachyarrhythmia [BC71] [61]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Epirubicin and Ganciclovir. Virus infection [1A24-1D9Z] [60]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Epirubicin and Valganciclovir. Virus infection [1A24-1D9Z] [60]
⏷ Show the Full List of 278 DDI Information of This Drug

References

1 New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133.
10 Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101.
11 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
12 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
15 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
16 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
17 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
18 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
19 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
20 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
21 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
22 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
23 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
24 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
25 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
26 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
27 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
28 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
29 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
30 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
31 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
32 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
33 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
34 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
35 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
36 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
37 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
38 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
39 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
40 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
41 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
42 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
43 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
44 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
45 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
46 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
47 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
48 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
49 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
50 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
51 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
52 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
53 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
54 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
55 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
56 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
57 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
58 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
59 Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
60 Cerner Multum, Inc. "Australian Product Information.".
61 Canadian Pharmacists Association.
62 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
63 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
64 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
65 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
66 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
67 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
68 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
69 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
70 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
71 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
72 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
73 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
75 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
76 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
77 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
78 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
79 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
80 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
81 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
82 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
83 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
84 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
85 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
86 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
87 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
88 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
89 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
90 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
91 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
92 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
93 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
94 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
95 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
96 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
97 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
98 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
99 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
100 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
101 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
102 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
103 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
104 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
105 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
106 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
107 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
108 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
109 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
110 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]